Barclays reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report report published on Sunday morning. The firm currently has a $30.00 price objective on the biopharmaceutical company’s stock.
A number of other brokerages have also recently weighed in on SGMO. Wedbush restated a hold rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. BidaskClub cut Sangamo Therapeutics from a buy rating to a hold rating in a research note on Wednesday, January 10th. Zacks Investment Research cut Sangamo Therapeutics from a buy rating to a hold rating in a research note on Friday, January 5th. Piper Jaffray Companies set a $25.00 price objective on Sangamo Therapeutics and gave the stock a buy rating in a research note on Wednesday, January 3rd. Finally, Jefferies Group restated a buy rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sangamo Therapeutics presently has a consensus rating of Buy and a consensus price target of $20.50.
Shares of Sangamo Therapeutics (NASDAQ:SGMO) opened at $23.45 on Friday. Sangamo Therapeutics has a 1-year low of $3.85 and a 1-year high of $27.50. The firm has a market capitalization of $2,108.80, a price-to-earnings ratio of -33.50 and a beta of 2.87. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64.
In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 16,630 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $16.13, for a total value of $268,241.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Edward R. Conner sold 5,000 shares of the stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $16.24, for a total value of $81,200.00. Following the completion of the sale, the vice president now owns 5,000 shares of the company’s stock, valued at $81,200. The disclosure for this sale can be found here. Insiders have sold a total of 94,403 shares of company stock valued at $1,779,959 over the last 90 days. 5.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in SGMO. New York State Common Retirement Fund raised its stake in Sangamo Therapeutics by 20.0% in the second quarter. New York State Common Retirement Fund now owns 76,200 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 12,699 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in Sangamo Therapeutics by 108.8% in the second quarter. UBS Asset Management Americas Inc. now owns 21,498 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 11,200 shares during the last quarter. Northern Trust Corp raised its stake in Sangamo Therapeutics by 4.9% in the second quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after buying an additional 44,656 shares during the last quarter. Vanguard Group Inc. raised its stake in Sangamo Therapeutics by 12.4% in the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after buying an additional 384,031 shares during the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in Sangamo Therapeutics in the second quarter valued at about $124,000. Institutional investors own 68.93% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics (SGMO) Earns Buy Rating from Barclays” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3227074/sangamo-therapeutics-sgmo-earns-buy-rating-from-barclays.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.